David A. Siegel Allovir, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Allovir, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 298,400 shares of ALVR stock, worth $220,816. This represents 0.0% of its overall portfolio holdings.
Number of Shares
298,400
Previous 98,800
202.02%
Holding current value
$220,816
Previous $67,000
237.31%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ALVR
# of Institutions
81Shares Held
49.1MCall Options Held
385KPut Options Held
2.3K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$8.36 Million0.24% of portfolio
-
Artal Group S.A. Luxembourg, N46.6MShares$4.88 Million0.27% of portfolio
-
Octagon Capital Advisors LP New York, NY4.2MShares$3.11 Million0.5% of portfolio
-
Black Rock Inc. New York, NY3.39MShares$2.51 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.94MShares$2.18 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $68.9M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...